Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

In this study, we investigated if Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, augments endometrial cancer (EC) therapy with medroxyprogesterone acetate (MPA). Combined treatment with Gefitinib plus MPA decreased the proliferation and invasiveness of the Ishikawa and RL952 EC cel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Yang, Yuan, Zhou, Jingyi, Li, Xiaoping, Zhao, Lijun, Cheng, Yuan, Lin, Yanying, Wang, Jiaqi, Wei, Lihui, Dong, Yafeng, Wang, Jianliu
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777777/
https://ncbi.nlm.nih.gov/pubmed/29383165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados